登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002399 证券简称：海普瑞 公告编号：2026-001 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、本期业绩预计情况 1、业绩预告期间：2025年1月1日至2025年12月31日。 2、业绩预告情况：预计净利润为正值且属于同向下降50%以上情形 特此公告。 深圳市海普瑞药业集团股份有限公司 二、与会计师事务所沟通情况 本次业绩预告相关数据未经会计师事务所预审计。公司已就业绩预告与会计师事务所进行了预沟通，双 方在本次业绩预告方面不存在分歧。 三、业绩变动原因说明 报告期内，本集团在全球肝素制剂市场业务拓展成果显著，各区域销售表现稳步向上，市场占有率持续 提升，依诺肝素制剂销量取得两位数增长，进一步巩固了本集团的全球竞争地位。 报告期内，公司归属于上市公司股东的净利润同比有所下降，主要是去年同期存在超过人民币3.5亿元 的一次性投资收益（非经常性损益），从而形成了较高的基数。此外，报告期内公司旗下联营公司因研 发进展未达预期，预计将对本集团净利润造成一定影响，具体影响以会计师事务所最终确认为 ...

中证智能财讯海普瑞（002399）1月30日晚间披露2025年度业绩预告，预计2025年归母净利润2.84亿元至3.77亿元，同比下降41.71%-56.09%；扣非净利润预 计3.62亿元至4.6亿元，同比增长42.78%-81.43%；基本每股收益0.1936元/股-0.2569元/股。以1月30日收盘价计算，海普瑞目前市盈率（TTM）约为48.14 倍-63.91倍，市净率（LF）约1.47倍，市销率（TTM）约3.36倍。 以本次披露业绩预告均值计算，公司近年市盈率（TTM）图如下所示： 近年来市盈率变化情况（倍） 90 77.64 78.95 @ 60 43°Ca 32.29 30.12 30 =25:62 23d04 0 -18.31 -30 -60 -90 -120 2022-06-30 ' 2021-06-30 ' 2021-12-37 2020-12-37 2022-12-37 : 23-72-37 3-06-30 2n- -○- 公司 -○- 行业均值 100 ହ 90 85p26 84.96 80 70 60 56.46 50 40 37.57 32401 30 20 2020-12-3 ...

报告期内，公司归属于上市公司股东的净利润同比有所下降，主要是去年同期存在超过人民币3.5亿元 的一次性投资收益(非经常性损益)，从而形成了较高的基数。此外，报告期内本公司旗下联营公司因研 发进展未达预期，预计将对本集团净利润造成一定影响，具体影响以会计师事务所最终确认为准。 报告期内，本公司归属于上市公司股东的扣除非经常性损益的净利润较去年同期实现增长，主要是主营 业务收入与利润的稳步提升。同时，本公司持续通过强化财务管理及优化资源分配，进一步提升营运效 率，推动盈利能力的持续改善。尽管联营公司预计将对本集团扣除非经常性损益后的净利润产生一定影 响，但本集团仍实现了扣除非经常性损益后净利润的稳健增长，展现出主营业务的经营韧性与持续增长 能力。 智通财经APP讯，海普瑞(09989)发布公告，该公司预计截至2025年12月31日止年度归属于上市公司股东 的净利润人民币2.84亿元-人民币3.77亿元，同比下降41.71%-56.09%。 报告期内，本集团在全球肝素制剂市场业务拓展成果显著，各区域销售表现稳步向上，市场占有率持续 提升，依诺肝素制剂销量取得两位数增长，进一步巩固了本集团的全球竞争地位。 ...

Summary of the Conference Call for Jianyou Co., Ltd. Industry and Company Overview - Jianyou Co., Ltd. is a leading integrated player in the heparin raw materials and formulations industry, benefiting from a stabilized recovery in heparin raw material prices and solidifying profitability in traditional business segments [2][5][6]. Core Insights and Arguments - **High-end Injection Export Growth**: The high-end injection segment is identified as the second growth engine for Jianyou. The approval of Enoxaparin formulations in the US and European markets has led to rapid growth, with 82 US-approved varieties expected by the end of 2024 [2][6]. - **Expansion in Non-Heparin Products**: Jianyou is expanding its product pipeline in the non-heparin sector, averaging about 10 new ANDA varieties annually. The company is positioned to capture a larger market share, with significant growth potential compared to leading companies like Hikma [2][7]. - **Cost Advantages**: Chinese companies, including Jianyou, have a significant advantage in comprehensive manufacturing costs, which is expected to lead to higher profitability levels as they catch up with competitors like Hikma [2][7]. - **Biologics and Biosimilars Strategy**: Jianyou is strategically positioning itself in the biosimilars and innovative biologics sectors, leveraging its injection export resources. The US biosimilars market is projected to exceed $40 billion by 2027, presenting substantial growth opportunities [2][9]. - **Future Profitability Expectations**: The company is projected to achieve a net profit of approximately 1 billion yuan in 2025, supported by clear international growth potential in high-end formulations and favorable industry policies [3][10]. Additional Important Points - **Historical Context and Growth Model**: Jianyou has a rich history dating back to 1991, with a proven growth model and core competencies that have been validated over time. The current stock price is at a historical low, suggesting a potential investment opportunity [4]. - **Integrated Business Model**: The company has established a comprehensive business model that encompasses research, production, and sales in the heparin raw materials sector, which has solidified its market position [5]. - **Market Penetration Strategy**: Jianyou has successfully established a local marketing system in the US through strategic acquisitions, enhancing its brand influence and market share [6]. This summary encapsulates the key points discussed in the conference call, highlighting Jianyou Co., Ltd.'s strategic positioning, growth potential, and market dynamics.

根据《证券期货投资者适当性管理办法》及配套指引，本资料仅面向华创证券客户中的金融机构专业投资者，请勿对本资料进行任何形式的转发。若您不是华创证券客户中的金融机构专业投资者，请勿订 阅、接收或使用本资料中的信息。 本资料难以设置访问权限，若给您造成不便，敬请谅解。感谢您的理解与配合。 摘要 高端注射剂平台建成，健友股份 3.0 To 2030 。 健友股份的前身健友生化厂于 1991 年成立，在创立以来三十余年的时间，公司始终保持 着前瞻的战略眼光和高效的执行力。目前健友股份产品管线丰富，业务涵盖无菌注射剂、肝素原料药、 CDMO 及生物药创新，立足中 美，拓展全球。回顾公司的发展历程，我们认为公司的成长模式和核心竞争力均已得到了较为充分的验证，并展现出广阔的成长空间。 原料药制剂一体化：肝素价稳筑基，制剂蓄势待发 。 健友股份作为国内肝素原料药及制剂一体化的龙头企业，凭借其在肝素产业链上的 完整布局，奠定了公司发展的坚实基础。公司不仅在肝素原料药领域占据重要地位，也通过制剂一体化战略，形成了从研发、生产到销 售的完整产业链条。 制剂出口 1 ：依诺肝素开篇，高端注射剂接力。 公司以依诺肝素制剂全球化突破为起点 ...

Core Viewpoint - The article emphasizes the growth potential and strategic positioning of Jianyou Co., highlighting its comprehensive capabilities in high-end injectable drugs and the integration of raw materials and formulations, particularly in the heparin sector, as well as its expansion into biosimilars and innovative drugs. Group 1: High-End Injectable Drug Platform - Jianyou Co. has established a high-end injectable drug platform, showcasing a rich product pipeline that includes sterile injectables, heparin raw materials, CDMO, and biopharmaceutical innovations, with a focus on expanding globally from a strong base in China and the U.S. [2][6] - The company has a solid foundation in the heparin industry, being a leading player in the integrated raw material and formulation sector, which supports its growth trajectory [16][20]. Group 2: Export of Formulations - The company has successfully launched its enoxaparin formulations globally since 2019, becoming a key driver of overseas revenue growth, leveraging FDA/EMA certifications to access emerging markets [29][30]. - As of the end of 2024, Jianyou Co. has obtained 82 approved ANDA products in the U.S., with plans to accelerate penetration into Europe and emerging markets [29][35]. Group 3: Biosimilars and Innovative Drugs - Jianyou Co. is transitioning towards biosimilars and innovative drugs, capitalizing on its manufacturing expertise to explore broader market opportunities, particularly in the U.S. biosimilar market, which is projected to exceed $40 billion by 2027 [4][53]. - The company has made strategic acquisitions, such as the purchase of Coherus' adalimumab biosimilar, to enhance its market position in the U.S. [62]. Group 4: Financial Performance and Projections - For the first three quarters of 2024, the company reported revenues of 3.088 billion yuan, with a net profit of 606 million yuan, reflecting a year-on-year decline of 27.83% [10]. - The projected net profits for 2024-2026 are 816 million, 1.108 billion, and 1.478 billion yuan, respectively, indicating a recovery and growth trajectory [4][10]. Group 5: Market Position and Competitive Landscape - The U.S. injectable generic drug market is characterized by high barriers to entry, with significant growth potential, as evidenced by the market size of $15-20 billion and a projected CAGR in the high single digits [37][49]. - Jianyou Co. is positioned to compete effectively against established players like Hikma, with a focus on leveraging its integrated manufacturing and cost advantages to enhance profitability [49][50].